ORPHA:49804
Lichen amyloidosis
Also known as: Amyloid lichen · Lichen amyloidosus
Publications
824
80.5th percentile
Trials
2
Interventional, condition-specific
Researchers
963
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Lichen amyloidosis is a rare chronic form of cutaneous amyloidosis, a skin disease characterized by the accumulation of amyloid deposits in the dermis, clinically characterized by the development of pruritic, often pigmented, hyperkeratotic papules on trunk and extremities, especially on the shins, and histologically by the deposition of amyloid or amyloid-like proteins in the papillary dermis.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018856
- UMLS:C5779561
Additional Mondo synonyms (2)
amyloid lichen · lichen amyloidosus
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
824 matched papers (389 in last 10 years) Source
- Phenotype characterisedPresent
2 HPO annotations (e.g. Pruritus; Papule) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
824
824 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
824 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
389 in the last 10 years · high confidence · 80.5th percentile (publications denominator)
Phrase hits: 824 · MeSH hits: 0
Who's working on it?
963
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li F6 papers · 2025
Department of Oncologic and Urologic Surgery, The 903rd PLA Hospital, Wenzhou Medical University, 40 Jichang Road, Hangzhou, 310004, Zhejiang Province, China.
Papers in Europe PMC - 02Mathiesen JS5 papers · 2025
Department of ORL, Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.
Papers in Europe PMC - 03Wang H5 papers · 2026
Division of Thyroid Surgery, The China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Precision Medicine Laboratory of Molecular Biology and Translational Medicine on Differentiated Thyroid Carcinoma, Changchun, China.
Papers in Europe PMC - 04Lee JH4 papers · 2025
Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Papers in Europe PMC - 05Poulsen MM4 papers · 2025
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Papers in Europe PMC - 06Qi XP4 papers · 2021
Department of Oncologic and Urologic Surgery, The 903rd PLA Hospital, Wenzhou Medical University, 40 Jichang Road, Hangzhou, 310004, Zhejiang Province, China. qxplmd@163.com.
Papers in Europe PMC - 07Rasmussen ÅK4 papers · 2025
Department of Endocrinology and Metabolism, Copenhagen University Hospital, Copenhagen, Denmark.
Papers in Europe PMC - 08Rossing M4 papers · 2025
Center for Genomic Medicine, Copenhagen University Hospital, Copenhagen, Denmark.
Papers in Europe PMC - 09Cao ZL3 papers · 2021
Department of Oncologic and Urologic Surgery, The 903rd PLA Hospital, Wenzhou Medical University, 40 Jichang Road, Hangzhou, 310004, Zhejiang Province, China.
Papers in Europe PMC - 10Feldt-Rasmussen U3 papers · 2025
Department of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Institute of Clinical Medicine, Faculty of Health Sciences, Copenhagen University, Copenhagen, Denmark.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; none in our sample are currently recruiting. 367 trials are registered for amyloidosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
high confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: amyloidosis
367
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05019027·ENROLLING BY INVITATION·N-of-1 for Beta-Blockers in Cardiac Amyloidosis
Not reviewed·Conditions: Cardiac Amyloidosis · Heart Diseases · TTR Cardiac Amyloidosis·Matched via name phrase
- NCT06022939·RECRUITING·Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Not reviewed·Conditions: AL Amyloidosis·Matched via name phrase
- NCT07266116·RECRUITING·Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
Not reviewed·Conditions: Systemic Light Chain Amyloidosis·Matched via name phrase
- NCT07055724·NOT YET RECRUITING·Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
Not reviewed·Conditions: AL Amyloidosis·Matched via name phrase
- NCT07052903·RECRUITING·TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Not reviewed·Conditions: Transthyretin Amyloidosis With Cardiomyopathy·Matched via name phrase
- NCT06629818·RECRUITING·Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)
Not reviewed·Conditions: Light Chain (AL) Amyloidosis·Matched via name phrase
- NCT07624760·NOT YET RECRUITING·Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging
Not reviewed·Conditions: Monoclonal Gammopathy · Monoclonal Gammopathy of Undetermined Significance (MGUS) · Multiple Myeloma · AL Amyloidosis·Matched via name phrase
- NCT07638683·RECRUITING·A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
Not reviewed·Conditions: Multiple Myeloma · AL Amyloidosis·Matched via name phrase
- NCT07504289·NOT YET RECRUITING·CAR-NK Therapy for Cardiac Amyloidosis
Not reviewed·Conditions: Light Chain Cardiac Amyloidosis·Matched via name phrase
- NCT06907186·RECRUITING·An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With Cardiomyopathy
Not reviewed·Conditions: Hereditary Transthyretin Amyloidosis·Matched via name phrase
- NCT06998875·RECRUITING·A Prospective Cohort Study on Primary Cutaneous Amyloidosis
Not reviewed·Conditions: Primary Cutaneous Amyloidosis·Matched via name phrase
- NCT04991103·RECRUITING·Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Not reviewed·Conditions: Multiple Myeloma · Amyloidosis·Matched via name phrase
- NCT04935021·RECRUITING·Clinical Study of ATTR-CM
Not reviewed·Conditions: Transthyroxine Amyloidosis Cardiomyopathy·Matched via name phrase
- NCT04535349·RECRUITING·Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis
Not reviewed·Conditions: Amyloidosis Transthyretin·Matched via name phrase
- NCT07250269·RECRUITING·Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Not reviewed·Conditions: Relapsed/Refractory AL Amyloidosis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Lichen amyloidosis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Lichen amyloidosis" OR "Amyloid lichen" OR "Lichen amyloidosus"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Lichen amyloidosis" OR "Amyloid lichen" OR "Lichen amyloidosus"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"amyloidosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T00:17:52.985Z
